title: [Meloxicam--the balance of efficacy and safety].
abstract: NSAIDs remain the principal pharmacological agents used for symptom relief in patients with rheumatic disease. They represent the largest single group of drugs used worldwide. Given the large number of available NSAIDs, it is unsurprising that some differences exist among them with regard to mechanism of action, pharmacokinetics, and tolerability. How these differences affect the overall risks and benefits of treatment continues to be examined in clinical trials. Meloxicam is COX-2 selective NSAID with favourable gastrointestinal and thromboembolic safety profile.
authors.affiliation: Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicka bolnica "Dubrava", Zagreb.
authors.forename: Jadranka
authors.initials: J
authors.lastname: Morović-Vergles
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077239:Meloxicam; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam